The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterizing the tumor and immune landscape of patients with melanoma treated with combined checkpoint blockade and MAPK-targeted therapy.
 
Liron Pola Zisman
No Relationships to Disclose
 
Irena Gushterova
No Relationships to Disclose
 
Thomas LaSalle
No Relationships to Disclose
 
Emily Blaum
No Relationships to Disclose
 
Tatyana Sharova
No Relationships to Disclose
 
Mofei Liu
No Relationships to Disclose
 
Anita Giobbie-Hurder
No Relationships to Disclose
 
Moshe Sade-Feldman
Consulting or Advisory Role - Galvanize Therapeutics
Research Funding - Calico
 
Keren Yizhak
No Relationships to Disclose
 
Nir Hacohen
Stock and Other Ownership Interests - BioNTech (I)
Consulting or Advisory Role - Immune Repertoire Medicines, Danger Bio, CytoReason
Research Funding - Calico Life Sciences, Bristol Myers Squibb
Patents, Royalties, Other Intellectual Property - BioNTech
 
Ryan J. Sullivan
Consulting or Advisory Role - Bristol-Myers Squibb; maren; Merck; Novartis; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)